Navigation Links
Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor

LONDON, April 4, 2007--Treatment data from Synovate Healthcare’s European Oncology Monitor reveals that over 10,000 breast cancer patients in the UK could become eligible for a breast cancer treatment showing lower death rates in patients. The treatment was the subject of a recent study detailed in the online edition of The Lancet (12 February 2007). Lower mortality rates were shown in patients who had switched to the aromotase inhibitor, Aromasin (exemestane), after 2-3 years of the current standard hormone drug therapy, tamoxifen. Aromasin was recently approved by the National Institute for Clinical Excellence (NICE).

Patients who could be eligible in this new indication were defined as newly diagnosed women in early stage disease who test positive for markers indicating hormone therapy as a treatment option, as well as those who have been on tamoxifen for 3 years or less. According to Synovate Healthcare’s data, 80% of drug-treated patients diagnosed in early stages are hormone responsive. Types of hormone therapies include tamoxifen and three aromatase inhibitors recently approved by the NICE. About 13% of newly diagnosed early stage breast cancer patients receive tamoxifen therapy in the UK annually.

Cancer Research UK and Globocan statistics from the World Health Organisation suggest that over 40,000 cases of breast cancer are diagnosed in the UK each year. Synovate Healthcare data shows that over 23,000 newly diagnosed patients are treated with drug therapies. Using data on the number of newly diagnosed women in early stage disease, together with the number of existing patients on tamoxifen, Synovate Healthcare estimates that over 10,000 breast cancer patients in the UK could become eligible for this new treatment within the next year.

Leah Krukowski, Head of Synovate Healthcare’s European Oncology Monitor, commented, “It is encouraging to see how many peoples& rsquo; lives could be positively affected by this treatment.” The European Oncology Monitor is an anonymous patient diary study run continuously in the UK, France, Germany, Italy and Spain, updated on a monthly basis.

Please note sample sizes: 2005 Q4 to 2006 Q3 = 1496 UK patients

- Ends -

About the Synovate Healthcare Global Oncology Monitor

The Synovate Healthcare Global Oncology Monitor covers 10 countries globally (UK, France, Italy, Germany, Spain, US, Japan, Australia, China and Korea) and is subscribed to by 50 companies worldwide. It is the largest and most frequently updated international drug-treated oncology patient sample.

About Synovate Healthcare

Synovate Healthcare is the global specialist healthcare market research arm of Synovate, dedicated to delivering marketing insights to the pharmaceutical and healthcare industries. Synovate Healthcare employs some 500 healthcare market research professionals across Europe, US and Asia Pacific and offers global fieldwork capabilities. For further details, visit www.synovate.com/healthcare.

About Synovate

Synovate is the market research arm of Aegis Group plc that generates consumer insights which drive competitive marketing solutions. The network provides clients with cohesive global support and a comprehensive suite of research solutions. Synovate employs over 5,000 staff in more than 100 offices across 50+ countries. More information on Synovate can be found at www.synovate.com.

www.synovate.com/healthcare

Telephone: +44 (0) 20 8246 6200
Fax: +44 (0) 20 8246 6300

Leah Krukowski
leah.krukowski@synovate.com
Tel: +44 208 246 6200


'"/>




Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
4. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
5. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
6. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
7. Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds
8. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
9. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
10. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The book, ... for IT services, what questions to ask your IT consultant before signing a contract ... to your computer network. , “With companies relying heavily on e-mail and technology, it’s ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):